UTHR United Therapeutics Corp. Gross Profit Rate

Corporate emblem and logo of United Therapeutics Corp. (UTHR)

United Therapeutics holds the status of a lifesaver in the treatment of rare lung pathologies, enjoying the absolute trust of physicians. The gross profit margin demonstrates the efficiency of this model, where 86.30 determines the current status of the parameter. Growth is driven by the dominance of Tyvaso and a breakthrough in xenotransplantation, although stability requires the monitoring of patent protection while maintaining a safe financial balance.

United Therapeutics (UTHR): Gross Margin from 07/04/2022 to 11/20/2026

Analytical breakdowns and data insights for company United Therapeutics Corporation (UTHR)

- market value and analyst target forecast:
Fundamental valuation:UTHR - United Therapeutics Corp.
Manufactured product of unither.com

Gross margin measures the portion of revenue remaining after covering direct production costs, determining the fundamental efficiency of the business model. For United Therapeutics (UTHR), this metric reflects the company's ability to pass the costs of complex cold-chain logistics for life-saving drugs onto the end consumer. Analyzing gross profit margins allows for the rapid identification of rising costs of goods sold or a decline in pricing power. Consistently high values confirm high added value and the financial stability of the asset.